Abstract: Methods were developed for the determination of urinary phenylmercapturic acid (PMA), a metabolite specific for benzene, benzylmercapturic acid (BMA), a metabolite of toluene and phenylhydroxyethylmercapturic acids (PHEMAs), specific for styrene, in human beings. Methods involved sample clean up followed by deacetylation and derivatization of the compounds with ophthaldialdehyde and 2-mercaptoethanol.
Introduction
The role of glutathione (GSH) in the detoxification processes of electrophilic compounds, both endogenous and exogenous, is well documented in literature' ' 2) . Among the exogenous chemicals, benzene, toluene, and styrene have been shown to interact with GSH, not directly but by conjugation of reactive electrophilic intermediates2' 3) (Fig.  1) . The reactive intermediate of benzene is benzene epoxide, the reactive intermediate of toluene is probably benzyl sulfate, and the intermediate of styrene is styrene 7,8-epoxide. The subsequent metabolization of GSH-adducts leads to the urinary excretion of specific mercapturic acids. Thus benzene and toluene to S-phenylmercapturic acid (PMA) and S-*To whom correspondence should be addressed , benzylmercapturic acid (BMA), respectively. Styrene is metabolised to phenylhydroxyethylmercapturic acids (PHEMAs), namely N-acetyl-S-(1-phenyl-2-hydroxyethyl)-cysteine (Ml) and N-acetyl-S-(2-phenyl-2-hydroxyethyl)-cysteine (M2), which are regioisomers4~. As a consequence of the chiral nature of styrene 7,8-epoxide, which is present in two enantiomeric forms [(R)(+) and (S)(-)], the mercapturic acids of styrene consist of two diastereoisomers4 ' 5) . Altogether, after styrene exposure four PHEMAs are excreted in urine, namely M1-"R", M1-"S", M2-"R", and M2-"S"; in this context, the labels -"R" and -"S" refer exclusively to the compounds derived from (R)(+)-and (S)(-)-styrene 7,8-epoxide respectively. The conversion rates of benzene, toluene, and styrene to mercapturic acids in humans are believed to be lower than 1 thus the measurement of urinary mercapturic acids of these compounds in humans is a considerable analytical problem. The solution may represent a model to evaluate the excretion of the mercapturic acids specific for other compounds having metabolic pathways similar to those of the above chemicals. The analytical methods proposed in literature for the measurement of PMA, BMA and PHEMAs are based on Gas
Chromatography-Mass Spectrometry (GC-MS)1°-13), on Gas Chromatography-Electron Capture Detector (GC-ECD)14>, on Thin Layer Chromatography (TLC)9), or on High Performance Liquid Chromatography (HPLC) with Ultraviolet (UV)' 1' 15), fluorescence1~18), and electrochemical detectiong), but only GC-MS, GC-ECD and HPLCfluorescence detector seem useful to evaluate accurately the excretion of these metabolites in humans. The aim of this paper is to demonstrate the potentiality of the HPLCfluorescence technique for the measurement of the mercapturic acids specific for benzene, toluene, and styrene, and to show experimental data about the excretion of these compounds in exposed and in unexposed subjects; finally, the usefulness of the specific mercapturic acids as biological markers of environmental exposure to the above compounds will be critically evaluated.
Subjects and Methods
Chemicals o-Phthaldialdehyde (OPA), 2-mercaptoethanol (MCE), porcine acylase I (grade III) (EC 3.5.1.14) and N-acetyl-Lcysteine were from Sigma (Munich, Germany). Styrene 7,8-epoxide was from Aldrich (Steinheim, Germany).
Methanol and water were of HPLC grade (BDH, Pole, UK), while all other reagents and solvents were of analytical grade.
The derivatizing reagent was prepared by dissolving 50 mg of OPA in 0.3 ml of a 0.2% solution of MCE in methanol, then 2 ml of borate buffer (pH 10) were added. Centrifugal ultrafiltration units (Centrisart I, cut-off 10,000) were from Sartorius (Gottingen, Germany), disposable solid-phase extraction cartridges (Isolute C18-EC and SAX, 500 mg/3 ml) were purchased by International Sorbent Technology (Hengoed, UK). PMA and BMA standards were from Acros Chimica (Gee!, Belgium), while the crude PHEMAs standard (containing Ml-"R", Ml-"S", M2-"R" and M2-"S") was prepared by the method of Yagen et al. 4 ) and the four diastereoisomers were isolated by semipreparative HPLC18).
Apparatus
The HPLC system used to assay mercapturic acids consisted of a Waters 600E pump (Waters Milford, MA, USA), a Jasco 820-FP spectrofluorimeter (Jasco Tokyo, Japan) and a Waters Wisp 715 autosampler. A Gilson 201 fraction collector (Gilson Villiers-le-Bel, France) and a Waters 484 UV detector (set at 225 nm) were used for the sample clean-up prior to the determination of PHEMAs. The analytical columns were a Supelcosil C18, 150 x 4.6 mm, 3 um (Supelco, Bellefonte, USA) for PMA and BMA analysis, and an ODS-Hypersil, 250 x 4.6 mm, 3 µm (Shandon, UK) for PHEMAs assay.
The gas-chromatographic system consisted of a HP 5880 A chromatograph (Hewlett Packard Corp., USA) connected to a HP 5970 A mass selective detector for the environmental monitoring of benzene, toluene, and styrene, and of a DANI 8580 chromatograph (Dani Monza, Italy) equipped with a RD detector for the determination of urinary benzene.
Environmental air sampling and measurement of urinary benzene For each worker, exposure was estimated in breathing Measurement of PMA, BMA, and PHEMAs Urinary PMA and BMA could be measured by the same method, which involved a two-step purification of samples with reversed-phase and with strong anion exchange solidphase extraction cartridges. The sample clean-up prior to the analysis of PHEMAs was carried out by a chromatographic separation of urine samples. To the purified samples a solution of porcine acylase I was added and the mixture was shaken at 30°C for 90 min (for PMA and BMA) or at 37°C for 16 h (for PHEMAs). After centrifugal ultrafiltration, deproteinized samples were derivatized for 5 min with the OPA-MCE reagent and the fluorescent derivatives were separated on reversed-phase columns21, 22), Sample pretreatments and chromatographic conditions for the analysis of PMA, BMA, and PHEMAs are schematically summarised in Table 1 A and 1 B . Further details on the methods have been reported elsewhere16' t8). Subjects a) Evaluation of the background excretion All of the subjects examined were recruited from the University personnel who had no history of solvent exposure and alcohol consumption.
• First study: a single urine sample was collected for each of 42 nonsmokers and 45 smokers for the determination of PMA and BMA; in 20 smokers urinary benzene was also evaluated. • Second study: PMA and BMA excretion was monitored at three times through a one day period in 10 nonsmokers and 10 smokers; urine samples were collected in the morning, in the afternoon and in the evening.
• Third study: the background excretion of PHEMAs was evaluated in urine samples from 10 subjects, 5 smokers and 5 nonsmokers. b) Influence of ethanol on the excretion of BMA
• Four volunteers were experimentally exposed to toluene vapours (25 ± 1 ppm for 4 h) with and without simultaneous ethanol consumption (0.5 g ethanol/kg body weight in 50 ml orange juice administered by ingestion). The ethanol was ingested two minutes before entering the chamber and two hours after beginning of exposure. This intervals were chosen to produce a maximum and constant blood levels of toluene and ethanol at the same time. Each volunteer was studied twice, once after ethanol consumption, then as control of himself. The interval between the exposure session was 14 days, and the sessions were always carried out on the same day week for any subjects. Urine samples were collected before exposure, at the end of exposure, and at 6 h, 9 h and 17 h after the beginning of the exposure. All of the subjects gave their informed consent c) Monitoring of subjects occupationally exposed to benzene toluene or styrene • The excretion of PMA was measured in urine samples collected at the end of the workshift in 145 workers employed in a chemical plant, exposed to benzene and to low levels (<5 ppm) of toluene and xylenes.
• BMA was measured in 18 workers exposed to toluene at a glue factory; the co-exposure to other solvents was negligible.
• The determination of PHEMAs was carried out on 22 workers exposed to styrene in fiberglass-reinforced plastics factory; also in this case no exposure to other solvents was found with the exception of acetone (<25 Ppm). The TWA environmental concentration of benzene, toluene or styrene during the 8h-workshift was also estimated. Information on the workers' health status, smoking habits, and alcohol consumption was collected by means of a questionnaire during a medical examination: all of the subjects were apparently healthy, and the daily average consumption of ethanol was always less than 50 g.
Urine samples for the determination of mercapturic acids (10 ml) were kept frozen until they were analysed; urinary creatinine was measured by the method of Jaffe'. where:
CU=urinary concentration of PMA or PHEMAs; Ca= environmental concentration of benzene or styrene; R= retention index of benzene or styrene (0.50 and 0.64, respectively); vm=mean urinary flow-rate (about 1 mi/min); Vm=mean pulmonary ventilation (about 151/min).
Results

Performance of the analytical methods
The sample clean-up procedure described for PMA and BMA (Table 1A) gave highly purified samples with high recovery rates of the analytes [90.0 ± 3.8% and 94.2±4.3%
(mean ± standard deviation, n=7) for PMA and BMA, respectively] and a close linearity of the calibration curves was found (r=0.9997 and 0.9998, respectively) up to at least 2000 µg/l of PMA and BMA. A good accuracy was found, in fact the percent error of the observed mean concentration vs the theoretical one was less than 6% at 10 ,ug/1 and less than 3% at 1,500 tg/l. The detection limit of the method was 0.5 ug/l for both PMA and BMA. The enzymatic deacetylation of the analytes reached a "plateau" after 90 min at 30°C. This finding was in agreement with data on other substrates22~. Like most OPA-MCE derivatives, also the fluorescent derivatives of PMA and BMA showed a longterm instability21>: after about 50 min the peak areas were one-half than after 2 min. A carefully control of reaction time prior to injection was needed to obtain reproducible results. Figure 2 shows some examples of profiles obtained from urine samples. The peaks of the fluorescent derivatives of PMA and BMA were free from any interfering compounds. No liquid-liquid or solid-phase extraction gave samples pure enough to allow a subsequent analysis of PHEMAs, thus a chromatographic technique was necessary for sample cleanup; by the method, shown in Table l B, highly purified samples were obtained with a quantitative recovery (>99%) of the analytes. Unfortunately low affinity was found between acylase I and PHEMAs, thus the deacetylation reaction reached a "plateau" only after 16 h at 37°C. The possibility of performing a chemical deacetylation with HCl at high temperature was checked, but the analytes showed a partial (and not reproducible) decomposition, so that this alternative was discarded. Even after sample clean-up, the chromatographic separation of the fluorescent derivatives of PHEMAs needed a complicated and time-consuming gradient run. The analytical conditions described in Table  1 B allowed to separate the peaks of M1-"R" and M1-"S" derivatives, while M2-"R" and M2-"S" derivatives eluted as a single peak (Fig. 3) (incidentally, if a chiral inversion of M2-"R" and M2-"S" has occurred during the reaction, then the same product could be formed by derivatization of these compounds). The method was less sensitive (detection limit=7 µg11) than the one developed for PMA and BMA and the calibration curves were linear up to 20,000 µg/l of PHEMAs (r=0.99997, 0.9998, and 0.9997 respectively for M1-"S", M1-"R", and M2). The reproducibility was evaluated at three concentration levels (from 312 to 8,460 µg/1) for each mercapturic acid of styrene, and samples were analysed five times: the coefficients of variation were below 7% for each compound. The accuracy of the method was estimated on two spiked samples (final theoretical concentration=50 and 10,000 pg/1) and the percent error was below 6% and 3%, respectively. The fluorescent derivatives of PHEMAs showed the same instability shown by the derivatives of PMA and BMA.
The column temperature strongly influenced the retention times of the fluorescent derivatives of PMA, BMA, and PHEMAs, therefore it was mantained constant to achieve a good reproducibility of the analyses.
Measurement of PMA excretion
The background excretion of PMA in smokers was significantly higher than that in nonsmokers (Table 2A ). In the urine of 20 smokers the concentration of PMA was correlated with the amounts of benzene excreted and the regression line equation was Y=0.0064 X + 1.220 (r=0.86), where Y=PMA (µg/g creatinine) and X=urinary benzene (ng/1). The results were not influenced by the sample collection point of time, and in fact the excretion of PMA was nearly constant during one day both in smokers and in nonsmokers (Table 2A ). The average excretion of PMA in urine samples taken from workers exposed to benzene was higher than the background amounts found in unexposed subjects and a strong correlation was found with the 8h-TWA environmental concentration of the solvent (Fig. 4a) . To minimise the effect of confounding factors (background excretion and smoking habit) the BTR of benzene to PMA was calculated on 68 nonsmokers exposed to at least 0.1 ppm of benzene. The BTR values of benzene to PMA at the end of the workshift ranged from 0.002 and 0.210% mean=0.073%) (Fig. 5a) . No correlation was found between environmental concentrations of benzene and BTR values.
No saturation of PMA excretion was observed at high exposure: this indicate that enzymatic conversion of benzene did not saturate even at high level of this solvent.
Measurement of BMA excretion
Most of unexposed subjects showed BMA values lower than 10 ~ug/g creatinine both in smokers and in nonsmokers, and no significant difference was found in samples collected at three intervals during one day; however it must be underlined that five subjects showed constantly a rather high excretion of BMA (>20 ,ug/g creatinine) ( Table 2B) . The experiment performed on four volunteers clearly demonstrated a strong influence of alcohol on BMA excretion, the highest concentration of the metabolite being, on average, 29.2 and 132.9 ,ug/g creatinine, respectively after toluene and toluene plus ethanol administration (Table 2B ). The amounts of urinary BMA in 18 workers exposed to toluene was higher, on average, than the basal excretion in unexposed subjects and a correlation was found between urinary BMA and 8h-TWA environmental concentration of the solvent (Fig. 4b) . Due to the interindividual variability of the background BMA excretion, an accurate estimation of BTR of toluene to BMA was not attempted, however the results suggested that BTR values were below 0.002%.
Measurement of PHEMAs excretion
In ten unexposed subjects no PHEMAs could be detected (Table 2C) . On the contrary, in all of the urinary samples taken from workers exposed to styrene the concentration of Ml-"R", M1-"S" and M2 was higher than the detection limit of the method (7 ~ug/1) (Table 2C) . A significant correlation was found between urinary levels of total PHEMAs and environmental concentration of styrene (r=0.45, p < 0.03), but with regard to the single compounds, only M2 showed a moderate correlation with exposure levels (Fig. 4c) . The BTR values of styrene to PHEMAs at the end of the workshift were estimated on all of the workers and ranged between 0.021 and 0.325% (mean=0.128%) (Fig. 5b) . Also in this case, no saturation of the enzymatic metabolization of styrene at the high exposure levels was found.
Discussion
The analytical method developed for the measurement of PMA was sensitive enough to allow the determination of this metabolite in the urine of both exposed and unexposed subjects. The background excretion of PMA in nonsmokers was rather low and it was likely due to the environmental levels of benzene, which is an ubiquitous pollutant, especially in urban areas23~. The urinary levels of PMA in smokers were well correlated with the amounts of benzene excreted in urine, and the mean concentration of the metabolite in smokers was about seven fold higher than in nonsmokers, whenever the sample was collected. These results are in contrast with some authors6~, but they are in agreement with other findings24>. The data confirmed that active smoking is an important source of non-occupational exposure to benzene. On one hand, this means that smoking must be considered a not negligible confounding factor for the biological monitoring of occupational exposure to low levels of benzene; on the other hand, the results confirm that the PMA test is sensitive and specific for benzene. The significant correlation found between excretion of PMA at the end of the workshift and environmental concentration of benzene support the hypothesis that the measurement of this metabolite could be useful as a biomarker of exposure to the solvent2$>. By the same method developed for the measurement of PMA it was possible to determine at the same time the BMA levels for both workers exposed to toluene and unexposed subjects. Most of the unexposed subjects showed BMA amounts lower than 10,ug/g creatinine; this is in agreement with recent reports12' 14) However in some cases the background excretion of BMA was rather high and not correlated with smoking or with the timing of sample collection. These apparently high levels of background excretion are unlikely attributable to the ubiquitous exposure to toluene in the air, taking into account the estimated low BTR of toluene to BMA (< 0.002%). The source of these high basal values remains unknown; the following could be the possible explanations of this finding: 1) they could be analytical artifactual; 2) they could be due to high toluene intake, also through routes other than the air; 3) they could reflect the ability of some individuals to metabolise toluene to BMA much more efficiently than the mean of the general population; 4) BMA could arise from the metabolism of chemicals other than toluene. The fourth possibility has been experimentally verified in animals at least in the case of benzyl alcohol3~, benzyl acetate26~, benzyl chloride27~, benzaldehyde28) and of N-nitroso-Nmethylbenzylamine, which is a benzylating compound suspected of being carcinogenic29~, it is possible that BMA is a common final product of different benzylating styrene to PHEMAs compounds. The urinary excretion of BMA in workers was correlated with the environmental levels of toluene, however the BMA test seems to have low specificity and sensitivity, therefore its use in the biomonitoring of exposure to the solvent is not recommended, taking into account the current threshold limit value (50 ppm)30). The analytical method developed for the measurement of PHEMAs appeared more complicated than the method for the determination of PMA and BMA. It was sensitive enough to evaluate the excretion of PHEMAs in workers exposed even to low levels of styrene (the lowest environmental concentration found in the subjects examined was about one-fifth of the current threshold limit value30) It did not allow to evaluate the actual background excretion of PHEMAs, which was always lower than the detection limit, thus it was not possible to check, for example, whether smoking could increase the basal excretion of these compounds. In our opinion, however, a background excretion of PHEMAs lower than 7,ug/1 should not represent a problem with regard to the possibility to use PHEMAs in the biological monitoring of occupational exposure to styrene. The little data available does not allow to draw a definitive conclusion, but it seems clear that a correlation exists between styrene intake and PHEMAs excretion, however only M2 appears significant correlated with the environmental levels of styrene, and even in this case the coefficient of correlation is lower than those which are usually found between styrene intake and the urinary excretion of other styrene metabolites31>. It is likely that the interindividual variability in the conversion of styrene to PHEMAs could play a role in determining such a low correlation, in fact a large variability is clearly shown by the rather broad range of BTR values (from 0.02 to 0.32%) (it must be pointed out that such a characteristic is evident also in the case of PMA, see below).
A peculiar phenomenon is represented by the stereoselectivity of the enzymes involved in the biotransformation of styrene to mercapturic acids, which is clearly shown at least in the case of M 1: the mean ratio of M1-"S" to M1-"R" was about 20 and values ranged from 7.8 to 41.0. A difference in toxicity and mutagenicity of the R(+) and S(-) enantiomers of styrene 7,8-epoxide has been reported32' 33) The large variability of the ratio of Ml-"S" and M-"R" could reflect a difference in the individual ability to conjugate GSH with the two enantiomers of styrene 7,8-epoxide and this could have some toxicological consequence.
Taking the data altogether, the GSH pathway appears to be involved to a minor extent in the detoxification of benzene, L MAESTRI et al.
toluene, and styrene, in fact very low mean BTR values were found: this is in agreement with previous reports6-9). However, Figure 5 clearly shows non-gaussian distribution patterns of BTR values and reveals that a not negligible fraction (up to one-third) of the population examined had moderate increase conversion rates. Such a result was not unexpected, if one considers the polymorphism of the glutathione-S-transferase isozymes involved in the conjugation of GSH with electrophilic intermediates: in most authors' opinion the general population could be divided into two groups, namely "slow" and "fast" converters, with regard to the individual ability to metabolise chemicals to mercapturic acids34). The biological and toxicological significance of this finding has to still be clarified: on one hand this could represent a restriction in the use of specific mercapturic acids as indices of exposure to xenobiotics, on the other hand it could be a useful tool in the individual risk assessment, if a different susceptibility to toxic compounds could be demonstrated between the two groups of "converters ." Toxicological properties of styrene 7,8-epoxide-GSH adducts have been also reported3' 36>, although at present these findings can not lead to any definitive conclusion about the risk assessment.
The experiment about the excretion of BMA after exposure to toluene and ethanol showed a noticeable influence of alcohol in the conversion of toluene to mercapturic acid. It is not clear whether this finding could be transferred also to benzene and styrene, given the different metabolic pathways involved before the conjugation step of the electrophilic intermediates with GSH ( Fig. 1) , however data on laboratory animals and on humans seems to indicate that the ingestion of alcohol could affect several metabolic pathways38-42); incidentally, also chronical exposure to styrene could modify the metabolism of this substance43) 
